News
0
Allergan performed an odd about-turn after initially declaring its interest in pursuing a deal for Shire, before reneging on that statement only a...
0
It's the end of another week and there's really been one story that has dominated the headlines – Takeda’s potential takeover of Shire. It should...
0
Eli Lilly and Incyte are facing more complications in the US approval of their experimental rheumatoid arthritis (RA) drug baricitinib after the...
0
A research team in Basel have developed an exciting new skin implant which can serve as an early warning system for four of the most common cancers...
Features
Norton Rose Fulbright’s Dominic Stuttaford, James Baillieu and Susie Brain discuss the implications regarding the recent reforms to cross-border...
Featured Appointment
Immunomedics hasn’t had the most straight forward year, its $2 billion deal with Seattle Genetics was scuppered by activist investors, which...
Service Company News
Featured Event
@Pharmafocus
